ArriVent BioPharma, Inc. (NASDAQ:AVBP - Get Free Report)'s share price reached a new 52-week low on Monday . The stock traded as low as $14.34 and last traded at $16.16, with a volume of 429 shares changing hands. The stock had previously closed at $16.42.
Analyst Upgrades and Downgrades
A number of equities research analysts recently commented on AVBP shares. HC Wainwright reissued a "buy" rating and issued a $39.00 price objective on shares of ArriVent BioPharma in a research note on Friday, March 7th. B. Riley assumed coverage on ArriVent BioPharma in a research report on Thursday, March 20th. They set a "buy" rating and a $37.00 price objective for the company. Finally, Guggenheim initiated coverage on ArriVent BioPharma in a research note on Monday, March 10th. They issued a "buy" rating and a $45.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus target price of $39.00.
Read Our Latest Stock Analysis on ArriVent BioPharma
ArriVent BioPharma Price Performance
The stock has a market cap of $617.39 million, a price-to-earnings ratio of -7.06 and a beta of 1.66. The stock's 50-day moving average is $21.88 and its 200-day moving average is $25.87.
ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.18. Analysts predict that ArriVent BioPharma, Inc. will post -2.74 EPS for the current fiscal year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of ArriVent BioPharma in the fourth quarter worth approximately $31,000. Tower Research Capital LLC TRC boosted its holdings in shares of ArriVent BioPharma by 773.8% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,599 shares of the company's stock valued at $43,000 after purchasing an additional 1,416 shares during the last quarter. Virtus ETF Advisers LLC purchased a new stake in shares of ArriVent BioPharma during the 4th quarter valued at $73,000. KLP Kapitalforvaltning AS acquired a new stake in shares of ArriVent BioPharma during the 4th quarter worth $83,000. Finally, China Universal Asset Management Co. Ltd. purchased a new position in shares of ArriVent BioPharma in the 4th quarter worth $190,000. Institutional investors and hedge funds own 9.48% of the company's stock.
ArriVent BioPharma Company Profile
(
Get Free Report)
ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.
Featured Stories
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
